Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Intel Trader who wrote (4751)	7/6/1998 11:13:00 AM
From: Steve Fancy	Read Replies (2) \| Respond to of 6136

Intel, glad to see someone is feeling optimistic and putting their money where there mouth is. You feel this is initial disappointment selling? Does look like they're trying to take it back up. sf

To: Intel Trader who wrote (4751)	7/6/1998 11:18:00 AM
From: Steve Fancy	Respond to of 6136

IMMUNE RESPONSE CORP - AGOURON PHARMACEUTICALS INC - Encouraging Preliminary Clinical Results Immune-Based Therapy Remune [81] Canadian Market News from Market News Publishing, Monday, July 06, 1998 at 11:09 Immune Response Corporation and Agouron Pharmaceuticals Inc. announces that according to a preliminary report at the 12th World AIDS Conference in Geneva, patients treated with antiretroviral combination therapy developed large immune responses to HIV as measured by lymphocyte proliferation and beta-chemokine production and experienced more frequent drops in plasma HIV below the level of detection when their drug therapy was accompanied by REMUNE (the IRC HIV immunogen), an immune-based therapeutic agent being developed by The Immune Response Corporation and Agouron Pharmaceuticals, Inc. Fred Valentine, M.D., Professor of Medicine, New York University Medical Center reported preliminary results from a multi-center randomized, double-blind, placebo controlled phase II study of 43 HIV-infected patients (median viral load of 8159 copies/ml, median CD4+ T-cells of 493 cell/mm3) treated with highly active antiretroviral drug therapy (HAART) consisting of zidovudine (AZT) + lamivudine (3TC) + indinavir. After four weeks of HAART treatment, these patients were randomized to receive the IRC HIV immunogen or a placebo administered by intramuscular injection every three months. Sixteen weeks after commencement of the study, 86% (18/21) of patients receiving both the IRC HIV immunogen and HAART had viral loads (the amount of HIV in plasma) below the limit of detection by an ultrasensitive assay (<40 copies/mL), compared to 67% (12/18) of patients receiving HAART alone. CD4+ T-cells were measured at week 20. Mean increases for the group receiving the IRC HIV immunogen-containing regimen and the control group were similar at 137 and 109 cells/mm3, respectively. The HAART + IRC HIV immunogen treatment group experienced a statistically significant improvement in several markers of immunologic response such as lymphocyte proliferation to HIV antigens and responses to native p24, gpl20-depleted HIV, and whole BaL HIV. No significant difference in more general immune responses to candida, streptokinase or tetanus antigens was observed between groups. Additionally, patients receiving HAART + the IRC HIV immunogen experienced significant increases in production of MIP-1 beta (a beta-chemokine associated with viral suppression) compared to the HAART + placebo group. "This HIV-specific lymphocyte proliferative immune response in patients receiving the IRC HIV immunogen + HAART," commented Dr. Valentine, "is comparable to that seen in some individuals with nonprogressive disease." This 32 week study was designed and initiated at the New York University Medical Center in New York; the North Shore University Hospital in Manhasser, New York, the Johns Hopkins University School of Medicine in Baltimore, the Chicago Medical School, the Center for Blood Research in Boston, the University of California at Irvine, the University of California at Davis, and the Institute for Human Virology in Baltimore also participated. New York University Medical Center is one of the nation's leading biomedical resources, combining excellence in patient care, research and medical education. TEL: (212) 263-5800 New York University Medical Center Office of Public Affairs (c) 1998 Market News Publishing Inc. All rights reserved. Tel:(604) 689-1101 Fax:(604) 689-1106 RapidFAX (tm) - To get the NEWS as it happens, call (604) 689-3041.